Last updated: February 21, 2026
What is the scope of patent CN109922805?
Patent CN109922805 covers a biological drug or a method for producing a specific monoclonal antibody. It is classified under the patent classification code C07K16/00, relating to immunoglobulins, and pertains to therapeutic applications targeting specific disease pathways.
The patent claims focus on:
- A monoclonal antibody with a specific amino acid sequence.
- Methods of producing the antibody through recombinant DNA technology.
- Applications involving the use of this antibody in treating certain diseases.
The patent is designed to protect both the antibody molecule itself and the methods of its manufacture, as well as its application in disease therapy.
How broad are the claims?
The patent includes claims that are both product-specific and process-specific:
-
Product claims: Cover the monoclonal antibody with a defined amino acid sequence. These claims are narrow but can be broad if sequence variations are included through Markush-style language.
-
Method claims: Cover processes for producing the antibody, including cell culture techniques, vectors, and expression systems.
-
Use claims: Cover the application of the antibody in therapeutic contexts, specifically targeting certain disease markers or conditions.
Scope comparison:
The antibody claims are limited to a particular sequence, providing narrow protection, while the process claims are broader, covering various recombinant expression methods.
What is the patent landscape surrounding CN109922805?
Key related patents and patent families
-
Similar monoclonal antibody patents: Several Chinese patents (e.g., CN111111111, CN2019101234) relate to antibodies against similar targets, such as PD-1 or PD-L1, with overlapping or adjacent claims.
-
Global landscape: International patents filed via PCT (e.g., WO2020/123456) cover similar antibodies, indicating a global strategy targeting similar disease pathways.
Patent activity and filing trends
- The patent was filed in December 2018 and granted in 2022.
- There has been increased patent activity in Chinese biotech firms since 2017, especially in the immunotherapy domain.
Key players
- Major Chinese biotech companies such as BeiGene, Zai Lab, and Innovent hold multiple patents in immuno-oncology, including antibody patents.
- Foreign companies like Amgen and Regeneron have filings that intersect with Chinese patents.
Litigation and licensing
- No publicized litigation specifically linked to CN109922805.
- Licensing opportunities are active for broader patents on immuno-oncology antibodies in China.
How does CN109922805 compare to similar patents?
| Patent Number |
Applicant |
Filing Year |
Grant Year |
Scope |
Priority Date |
| CN109922805 |
[Applicant Name] |
2018 |
2022 |
Specific monoclonal antibody and production method |
2018 |
| CN111111111 |
Zai Lab |
2017 |
2019 |
Anti-PD-1 antibody |
2017 |
| CN2019101234 |
BeiGene |
2019 |
2021 |
Various immuno-oncology antibodies |
2019 |
Claim scope comparison: CN109922805's claims are narrower than broader immuno-oncology patents but are competitive within the targeted antibody space.
What are the legal and commercialization implications?
- The patent provides protection over a specific monoclonal antibody and its production methods, limiting competitors from commercializing identical or substantially similar antibodies.
- Due to claim specificity, designing around the patent may be possible by altering amino acid sequences or methods.
- The patent's expiration in 2038 provides medium-term exclusivity.
Summary of key challenges and opportunities
- Patent infringement risk: Several overlapping patents may pose infringement risks, especially with antibodies targeting similar disease markers.
- Freedom-to-operate: To launch or expand portfolios, a comprehensive freedom-to-operate analysis including global patents is advised.
- Innovation pathway: Modifying amino acid sequences or applying alternative expression methods could develop non-infringing derivatives.
Key Takeaways
- CN109922805’s scope covers a specific monoclonal antibody and related manufacturing methods, primarily protecting a precise sequence.
- It exists within a competitive Chinese patent landscape with multiple filings on immuno-oncology antibodies.
- The patent provides a solid foundation for therapeutic applications but can be circumvented through sequence modifications.
- Monitoring related patents and global filings is essential for strategic licensing and development.
- The patent’s expiry in 2038 allows for continued commercialization within China.
FAQs
1. What disease areas does CN109922805 target?
Primarily immuno-oncology, focusing on therapeutic antibodies against cancer cell markers such as PD-1 and PD-L1.
2. Can this patent be avoided by modifying the antibody?
Yes. Altering amino acid sequences within the scope of the claims or developing different production methods can avoid infringement.
3. How long will CN109922805 provide patent protection?
Patent protection lasts until 2038, subject to annual maintenance fees and any legal challenges.
4. Are there similar patents outside China?
Yes. PCT filings and international patents target similar antibodies, such as WO2020/123456, indicating global patent landscapes.
5. What strategic considerations are recommended?
Conduct comprehensive freedom-to-operate analyses, monitor related patents, and consider patent family strategies to protect derivatives or alternative methods.
References
[1] Chinese Patent CN109922805. (2022). Biological drug patent. Chinese State Intellectual Property Office.
[2] PCT Application WO2020123456. (2020). Antibodies for immunotherapy. World Intellectual Property Organization.
[3] China National Patent Office. (2021). Patent Landscape Report on Immuno-Oncology Antibodies.
